New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 30, 2013
05:52 EDTMYGNMyriad Genetics downgraded to Underperform at JMP Securities
JMP Securities downgraded Myriad Genetics to Underperform from Market Perform after the Centers for Medicare & Medicaid Services said Friday that the BRCA pricing was not a misprint. JMP sees little chance that the prices will revert to the previous level of around $2,900 for code 81211 and set a $15 price target for Myriad shares.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 7, 2014
16:34 EDTMYGNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
11:09 EDTMYGNMyriad Genetics advises prior BRACAnalysis news release be disregarded
Myriad Genetics advised that readers should disregard the news release, "Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis" issued April 7 by the company over GlobeNewswire.
10:16 EDTMYGNMyriad Genetics has a conference call hosted by JPMorgan
Subscribe for More Information
05:48 EDTMYGNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use